Doerte Wolf

Doerte Wolf, MD, a clinical pharmacologist, has been in the contract research business in leading capacities as Clinic Head and Principal Investigator for several years. Her experience includes responsibility for design, execution and evaluation of about 150 clinical trials phase I – III .

Doerte Wolf is managing partner of CardioSec

Doerte Wolf

Dr. Hans-Joachim Janhsen

Studied Pharmacy at the Freie Universität Berlin; Licensed Pharmacist (1981)

PhD in Science, Pharmaceutical Chemistry, Christian-Albrechts-Universität Kiel, Germany (1986)

Additional Qualification: Business Administration, University Lahr, Germany

Europe and the USA, 1983 to 2003: various positions including Managing Director and Member of the Board in the pharmaceutical industry, production and development, in internationally operating corporations (Schering, John&Johnson Merck, Gehe, Baxter),

- Consultant in the area of health care for the pharmaceutical industry, Managing Partner of CardioSec

Wilhelm Haverkamp

Prof. Dr. Wilhelm Haverkamp, is “Oberarzt” at the Department of Cardiology, Charite – Campus Virchow, Humboldt University of Berlin, Germany. Dr. Haverkamp has been actively involved in scientific research for the past 18 years. Since the late 1980’s, disturbances of myocardial repolarization and the effects of drugs on repolarization have become fields of special scientific interest. He was one of the organizers of the Policy Conference on “The Potential for QT Prolongation and Proarrhythmia by Non-Antiarrhythmic Drugs, Clinical and Regulatory Implications” held at the European Heart House in Sophia Antipolis, France, in June 1999. His scientific work is reported in over 180 publications in scientific journals. Dr. Haverkamp is a member of several cardiological societies. He is a Fellow of the European Society of Cardiology.

Wilhelm Haverkamp is scientific advisor to CardioSec.

Wilhelm Haverkamp

Franziska Haverkamp

Franziska Haverkamp, MD, is a cardiologist with many years of practical experience in electrocardiography, and the design, execution and evaluation of definitive QT-studies.

Franziska Haverkamp is shareholder of CardioSec and the founder and General Manager of ExCard Research GmbH

(C) 2007 - All rights reserved

Print this page